AstraZeneca’ Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has failed to demonstrate superiority against umeclidinium/vilanterol in treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in the phase IIIb trial.
Pfizer and Astellas Pharma have announced amendments to the protocols for two registrational phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).
Can-Fite BioPharma has enrolled and dosed the first patient in its phase 3 Comfort trial to evaluate its small orally bioavailable drug Piclidenoson (CF101) for the treatment of moderate-to-severe plaque psoriasis.
Merck has signed a clinical trial collaboration agreement with Rexahn Pharmaceuticals to assess the combination of RX-5902 (Supinoxin) and Keytruda (pembrolizumab) in a breast cancer trial.
The Heads of Medicines Agencies (HMA), a European network of the heads of the national competent authorities, has approved Sensorion's volunturary harmonization procedure (VHP) application to initiate a phase 2 trial for SENS-401 for the treatment of sudden sensorineural hearing loss (SSNHL) in adults.
Swiss clinical-stage biopharmaceutical firm AC Immune has announced two clinical milestone events related to ACI-24, its anti-Abeta vaccine against Alzheimer's disease and Abeta-related cognitive decline in Down Syndrome.
Immunocore, a T Cell Receptor (TCR) biotechnology company, said that it has dosed the first patient in a phase I study of IMCnyeso, an ImmTAC molecule, as part of a collaboration with GlaxoSmithKline (GSK).
Teva Pharmaceutical Industries and Regeneron Pharmaceuticals reported positive topline results for fasinumab from a phase 3 trial in patients with chronic pain from osteoarthritis (OA) of the knee or hip.
Novocure and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer.
Inovio Pharmaceuticals has dosed the first participant with PENNVAX-GP in a randomized clinical trial that will assess its ability to drive remission of HIV infection.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.